Although controversial, patient-focused discounts can play a valuable role in managed-markets programs
In whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully
A pronounced fascination with Apple Computer's iPad is focusing sales-IT efforts on mobility and data access; meanwile, online e-detailing offerings win more acceptance
Key priorities: cleansed data and consolidated databases
Nearly 30% of acquiring companies do not evaluate FCPA risks prior to an acquisition
While researchers study new pain-killing pathways, the pharma industry tries drug combinations and alternative-delivery mechanisms By Angelo DePalma, PhD
It's still early days in making medical marijuana--and cannabis-based pharmaceuticals--part of normal dispensing
Some state-level changes give an indication of what to prepare for
How to prepare for reporting and utilizing published data for business and compliance purposes
Pushing your frontline into a new frontier
A Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets
A double-digit growth rate through 2024 means boom times for drug-delivery devices and for contract manufacturing services
Global efforts to collect clinical data in a more standardized form will lead to more research innovation
Global industry will spend $8.36 billion on cold chain logistics this year
Resources for education about senior citizens and long-term care
Fees paid to FDA by small generic manufacturers are financially 'unfair'
Belief that today’s commercial model is “broken” elicits a wide range of responses from industry
By running Commercial Operations like a stand-alone business, executives can sharpen their focus on strategy, tactics and overall performance
Five reasons why the island can serve as key cog in the national medical supply chain
Disconnected business processes in contract administration, managed markets, rebates, sales compensation and related areas cause waste and inefficiency for company management
The emergence of specialty pharmacies, with fundamental differences from other types of pharmacy providers, warrants the establishment of manufacturer relationships
A complement to the classic randomized clinical trial may benefit drug commercialization